AbbVie to acquire Apogee for $135.11/share (~$10.9B); Q2 results reported

Apogee Therapeutics, Inc.

AbbVie to acquire Apogee for $135.11/share cash, ~$10.9B equity value; expected close Q3 2026.
Phase 2 APEX Part B met endpoints: 65.9% EASI-75 (41.9% placebo-adjusted) with mid-dose zumilokibart.
Cash $1.3B at June 30, 2026; Q2 net loss $85.9M vs $66.1M year ago.
Blackstone financing collaboration up to $1.3B non-dilutive for zumilokibart development.
Phase 3 initiation for zumilokibart in atopic dermatitis planned this year; EoE and asthma trials set.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.